Cargando…
Multiple doses of icatibant used during pregnancy
BACKGROUND: Hereditary angioedema (HAE) is a life-long disease that often manifests by puberty. Treatment of attacks is essential to improve quality of life and to decrease morbidity and mortality. During pregnancy, treatment is limited because multiple treatment options, including icatibant, are no...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OceanSide Publications, Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662544/ https://www.ncbi.nlm.nih.gov/pubmed/29070276 http://dx.doi.org/10.2500/ar.2017.8.0210 |
_version_ | 1783274649018171392 |
---|---|
author | Kaminsky, Lauren W. Kelbel, Theodore Ansary, Fay Craig, Timothy |
author_facet | Kaminsky, Lauren W. Kelbel, Theodore Ansary, Fay Craig, Timothy |
author_sort | Kaminsky, Lauren W. |
collection | PubMed |
description | BACKGROUND: Hereditary angioedema (HAE) is a life-long disease that often manifests by puberty. Treatment of attacks is essential to improve quality of life and to decrease morbidity and mortality. During pregnancy, treatment is limited because multiple treatment options, including icatibant, are not approved for use during pregnancy. OBJECTIVE: We report the outcomes of three pregnancies during which icatibant was used by a patient with HAE with normal C1-inhibitor for treatment of attacks. We also reviewed the literature for reports of icatibant use during pregnancy for outcomes and adverse events. METHODS: We report on a patient who treated herself with icatibant during three separate pregnancies. Postpartum follow-up verified the health of the mother and children. We also performed a complete literature search of medical literature data bases on icatibant use during pregnancy. RESULTS: The patient in our report administered multiple doses of icatibant during three pregnancies. The child born from the first pregnancy and the child from the third pregnancy were born at term and without congenital anomalies. The child from the second pregnancy was 1-month preterm. All three children were developmentally normal. The literature search identified two case reports and one abstract of limited icatibant use without adverse events during pregnancy in patients with HAE. These pregnancies resulted in the births of healthy infants. CONCLUSION: From a search of the literature, three cases of icatibant use during pregnancy resulted in healthy infants. In addition, we report that from icatibant use in three separate pregnancies, one infant was born prematurely, but there were no birth defects. From follow-up, the children continued meeting developmental milestones. This report adds to the acquisition of knowledge for drug adverse events during postmarketing surveillance for icatibant use during pregnancy. |
format | Online Article Text |
id | pubmed-5662544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | OceanSide Publications, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56625442017-11-01 Multiple doses of icatibant used during pregnancy Kaminsky, Lauren W. Kelbel, Theodore Ansary, Fay Craig, Timothy Allergy Rhinol (Providence) Articles BACKGROUND: Hereditary angioedema (HAE) is a life-long disease that often manifests by puberty. Treatment of attacks is essential to improve quality of life and to decrease morbidity and mortality. During pregnancy, treatment is limited because multiple treatment options, including icatibant, are not approved for use during pregnancy. OBJECTIVE: We report the outcomes of three pregnancies during which icatibant was used by a patient with HAE with normal C1-inhibitor for treatment of attacks. We also reviewed the literature for reports of icatibant use during pregnancy for outcomes and adverse events. METHODS: We report on a patient who treated herself with icatibant during three separate pregnancies. Postpartum follow-up verified the health of the mother and children. We also performed a complete literature search of medical literature data bases on icatibant use during pregnancy. RESULTS: The patient in our report administered multiple doses of icatibant during three pregnancies. The child born from the first pregnancy and the child from the third pregnancy were born at term and without congenital anomalies. The child from the second pregnancy was 1-month preterm. All three children were developmentally normal. The literature search identified two case reports and one abstract of limited icatibant use without adverse events during pregnancy in patients with HAE. These pregnancies resulted in the births of healthy infants. CONCLUSION: From a search of the literature, three cases of icatibant use during pregnancy resulted in healthy infants. In addition, we report that from icatibant use in three separate pregnancies, one infant was born prematurely, but there were no birth defects. From follow-up, the children continued meeting developmental milestones. This report adds to the acquisition of knowledge for drug adverse events during postmarketing surveillance for icatibant use during pregnancy. OceanSide Publications, Inc. 2017-10 /pmc/articles/PMC5662544/ /pubmed/29070276 http://dx.doi.org/10.2500/ar.2017.8.0210 Text en Copyright © 2017, OceanSide Publications, Inc., U.S.A. http://creativecommons.org/licenses/by-nc/4.0/ This work is published and licensed by OceanSide Publications, Inc. The full terms of this license are available at https://www.allergyandrhinology.com, and incorporate the Creative Commons License Deed: Attribution – Non-Commercial 4.0 Unported (CC BY-NC 4.0). By accessing the work you hereby accept the terms. Non-commercial uses of the work are permitted without any further permission from OceanSide Publications, Inc., provided the work is properly attributed. Any use of the work other then as authorized under this license or copyright law is prohibited. |
spellingShingle | Articles Kaminsky, Lauren W. Kelbel, Theodore Ansary, Fay Craig, Timothy Multiple doses of icatibant used during pregnancy |
title | Multiple doses of icatibant used during pregnancy |
title_full | Multiple doses of icatibant used during pregnancy |
title_fullStr | Multiple doses of icatibant used during pregnancy |
title_full_unstemmed | Multiple doses of icatibant used during pregnancy |
title_short | Multiple doses of icatibant used during pregnancy |
title_sort | multiple doses of icatibant used during pregnancy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662544/ https://www.ncbi.nlm.nih.gov/pubmed/29070276 http://dx.doi.org/10.2500/ar.2017.8.0210 |
work_keys_str_mv | AT kaminskylaurenw multipledosesoficatibantusedduringpregnancy AT kelbeltheodore multipledosesoficatibantusedduringpregnancy AT ansaryfay multipledosesoficatibantusedduringpregnancy AT craigtimothy multipledosesoficatibantusedduringpregnancy |